Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease

Gut

Volumn 43, Issue 3, 1998, Pages 375-382

  Reinisch, W ^a   Heider, K H ^b   Oberhuber, G ^a   Dejaco, C ^a   Mullner M ^a   Adolf, G R ^b   Gasche C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

CD44 variant 6; Differential diagnosis; Immunohistochemistry; Soluble CD44v6

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; HERMES ANTIGEN; MESALAZINE; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; COLITIS; COLON BIOPSY; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0031669685     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.3.375     Document Type: Article

References (56)

1. Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn's disease of the colon: one, two or many diseases? In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease. 4th edn. Baltimore: Williams and Wilkins, 1995:355-79.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37,1008-16.
3. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease - "colitis indeterminate". J Clin Pathol 1978;31:567-77.
4. Wells AD, McMillan I, Price AB, et al. Natural history of indeterminate colitis. Br J Surg 1991;78:179-81.
5. Cosnes J, Carbonell F, Beugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31.
6. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-92.
7. Hyman NH, Fazio VW, Tuckson WB, et al. Consequences of ileal pouch-anal anastomosis for Crohn's colitis. Dis Colon Rectum 1991;34:653-7.
8. Pooley N, Ghosh L, Sharon P. Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995;40: 219-25.
9. Seldenrijk CA, Meuwissen SGM, Schipper NW, et al. Value of counting colonie mucosal Ig-containing cells in differential diagnosis of chronic inflammatory bowel disease. J Clin Pathol 1992;45:241-7.
10. Mahida YR, Kurlac L, Gallagher A, et al. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991,32:1531-4.
11. Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992,102:1620-7.
12. Choy MY, Walker-Smith JA, Williams CB, et al. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990;31:1365-70.
13. Shanahan F, Duerr RH, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-61.
14. Vasihauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-19.
15. Matthes H, Ulrich K, Stallmach A, et al. MMP I mRNA expression is a predictive parameter to discriminate between ulcerative colitis and Crohn's disease [abstract]. Gastroenterology 1996;110:A959.
16. Mantyh CR, Vigna SR, Bollinger RR, et al. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995;109:850-60.
17. Theodossi A, Spiegelhalter DJ, Jass J, et al. Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut 1994;35:961-8.
18. Hata J, Haruma K, Suenaga K, et al. Ultrasonographic assessment of inflammatory bowel disease. Am J Gastroenterol 1992;87:443-7.
19. Rosenberg WMC, Prince C, Kaklamanis L, et al. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 1995;345:1205-9.
20. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
21. Henke CA, Roongta U, Mickelson DJ, et al. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrin and invasion into a fibrin matrix. J Clin Invest 1996;97:2541-52.
22. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4.
23. Jackson DG, Bell JI, Timans J, et al. Proteoglycan forms on the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995;128:673-85.
24. Mackay CR, Terpe H-J, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
25. Heider K-H, Hofmann M, Hors E, et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-33.
26. Heider K-H, Mulder J-WR, Ostermann E, et al. Splice variants for the surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 1996;31A: 2385-91.
27. Gotley DC, Fawcett J, Walsh MD, et al. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 1996;74:342-51.
28. Ilyas M, Abbasi AM, Talbot IC, et al. CD44v6 and CD44v3 expression in ulcerative colitis and Crohn's disease [letter]. Lancet 1995;346:256.
29. Papadogiannakis N, Gad A, Chenard M-P, et al. Expression of CD44 variants in differential diagnosis of ulcerative colitis and Crohn's disease [letter]. Lancet 1996;347:1413-14.
30. Cellier C, Patey N, Leborgne M, et al. In situ expression of CD44 in ulcerative colitis (UC) and colonic Crohn's disease (CD) [abstract]. Gastroenterology 1996;110:A880.
31. Heider K-H, Sproll M, Susani S, et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43:245-53.
32. Terpe HJ, Stark H, Prehm P, et al. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994;101:79-89.
33. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24:(suppl 170):2-6.
34. Le Berre N, Heresbach D, Kerbaol M, et al. Histological discrimination of idiopathic inflammatory bowel disease from other types of colitis. J Clin Pathol 1995;48:749-53.
35. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298;82-6.
36. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's diseuse activity index National Crohn's Disease Study. Gastroenterology 1976;70:439-44.
37. Hofmann M, Rudy W, Zöller M, et al. CD44 splice variants confer metastatic behaviour in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991; 51:5292-7.
38. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
39. Armitage P, Berry G. Diagnostic tests and screening procedures. In: Armitage P, Berry G, eds. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1994:522-9.
40. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
41. Kitano A, Oshitani N, Matsomoto T, et al. CD44 variants in ulcerative colitis and Crohn's disease [letter]. Lancet 1996; 348:266-7.
42. Fox SB, Fawcett J, Jackson DG. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-46.
43. Mulder JWR, Wielenga VJM, Polak MM, et al. Expression of mutant p53 protein and CD44 variant protein in colorectal tumorigenesis. Gut 1995;36:76-80.
44. Koopman G, Heider K-H, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993;177:897-904.
45. Weiss JM, Sleeman J, Renkl AC, et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blond dendritic cell function. J Cell Biol 1997;137:1137-47.
46. Zhang M, Wang MH, Singh RK, et al. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem 1997; 272:1413-46.
47. Nagel E, Bartels M, Pichlmayr R. Scanning electron-microscopic lesions in Crohn's disease: relevance for the interpretation of postoperative recurrence. Gastroenterology 1995;108:376-82.
48. Kaya G, Rodriguez I, Jorcano JL, et al. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev 1997;11:996-1007.
49. Ryder SD, Parker N, Ecclestone D, et al. Peanut lectin stimulates proliferation in colonie explants from patients with inflammatory bowel disease and colon polyps. Gastroenterology 1994;106:177-24.
50. Kim H, Yang XL, Rosada C, et al. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 1994; 310:504-7.
51. Ekbom A. Cancer in inflammatory bowel disease. Curr Opin Gastroenterol 1995;11:316-20.
52. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992;119:229-38.
53. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996;87:847-57.
54. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43. CD44, and CD16 from stimulated human granulocytes. J Immunol 1994;152: 1314-22.
55. Ristamäki R, Joensuu H, Salmi M, et al. Serum CD44 in malignant lymphoma: an association with treatment response. Blood 1994;84:238-43.
56. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54: 422-6.